HealthDay News — The US Preventive Services Task Force (USPSTF) recommends the use of low-dose aspirin as preventive medication after 12 weeks of gestation for persons at high risk for preeclampsia. This recommendation forms the basis of a draft recommendation statement published online February 23.

Jillian T. Henderson, PhD, MPH, from the Kaiser Permanente Center for Health Research in Portland, Oregon, and colleagues reviewed updated evidence on the effectiveness and potential harms of daily aspirin use in pregnancy to prevent preeclampsia-associated morbidity and mortality. Thirty-three studies met the inclusion criteria. Eighteen trials assessed aspirin effectiveness in individuals at increased risk for preeclampsia. Aspirin dosage ranged from 50 to 150mg/day. The researchers found that these interventions were associated with reduced risks for perinatal mortality, preterm birth, and small for gestational age/intrauterine growth restriction (pooled relative risks, 0.79, 0.80, and 0.82, respectively). A significant reduction was also seen in the risk for preeclampsia (pooled relative risk, 0.85). No clear evidence of harms associated with daily aspirin use taken during the second or third trimester of pregnancy was observed.

Based on these findings, the USPSTF concludes with moderate certainty that there is substantial net benefit for daily low-dose aspirin use in pregnant women at high risk for preeclampsia. Low-dose aspirin (81mg/day) is recommended after 12 weeks of gestation for individuals who are at high risk for preeclampsia (B recommendation).

The draft recommendation statement and evidence review have been posted for public comment; comments can be submitted from February 23 to March 22, 2021.


Continue Reading

Draft Evidence Review

Draft Recommendation Statement

Comment on Recommendation Statement